IMNNImunonSigning up patients
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Epithelial Ovarian Cancer · Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 500 (planned)
- Started
- Jul 9, 2025
- Main results expected
- Oct 31, 2032
- Fully finished
- Oct 31, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival
Measured over: 48 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06915025 · record last updated 2026-10-30 · checked 2026-11-09 15:47 UTC